ASCO’s “rock concert” moments came 17 years apart—in 2005 and 2022

DESTINY-04 results extend HER2-targeted therapy to a larger population in breast cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The plenary session at the ASCO 2022 annual meeting saw that rarest of things at a scientific conference: a standing ovation. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
George W. Sledge Jr., MD
Professor of Medicine, Stanford University School of Medicine
Table of Contents

YOU MAY BE INTERESTED IN

Pfizer External Research & Grants’ “Improving Breast Cancer Quality of Care via Meaningful Capacity Building in Sub-Saharan Africa,” powered by EveryGrant, has announced grants totaling more than $900,000 for addressing inequities and improving the quality of breast cancer care in Sub-Saharan Africa.
Legislation aimed at increasing access to breast and cervical cancer screening was introduced May 22 in the U.S. Senate. The bipartisan Screening for Communities to Receive Early and Equitable Needed Services, or SCREENS, for Cancer Act would reauthorize the National Breast and Cervical Cancer Early Detection Program, or NBCCEDP, for fiscal years 2026 through 2030. 
Thomas J. Lynch Jr. and Howard A. “Skip” Burris III lead two institutions that couldn’t be more different—an NCI-designated Comprehensive Cancer Center on one side of the country and a for-profit research enterprise on the other—but they stay up at nights worrying about the same thing.
George W. Sledge Jr., MD
Professor of Medicine, Stanford University School of Medicine

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login